



THOMSON REUTERS™

ENDNOTE®

Collect. Collaborate. Create. From Anywhere.

ADVANCE YOUR RESEARCH AND PUBLISH INSTANTLY



X6版新功能

PubMed資料可直接匯入

PubMed ▾

"H1N1 vaccine"

Search

RSS Save search Advanced

Help

[Choose additional filters](#)

Display Settings: ▾ Summary, 20 per page, Sorted by Recently Added

Send to ▾ **Filters:** [Manage Filters](#)

1

Text availability

Abstract available
Free full text available
Full text available

Publication dates

5 years
10 years
Custom range...

Species

Humans
Other Animals

Article types

Clinical Trial
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
Systematic Reviews

Results: 1 to 20 of 420

<< First < Prev

☒ 1. [An early \(3-6 weeks\) active surveillance study to assess the effectiveness of influenza vaccine Focetria\(®\) in a province of Emilia-Romagna, Italy](#)

Candela S, Pergolizzi S, Ragni P, Cavuto S, Nobilio L, Groth N, Magrini N; for the SaFoH1N1 working group. Vaccine. 2012 Jul 2. [Epub ahead of print]
PMID: 22766247 [PubMed - as supplied by publisher]
[Related citations](#)

☒ 2. [Effectiveness of H1N1 vaccine for the prevention of influenza in Scotland, UK: a retrospective observational cohort study](#)

Simpson CR, Ritchie LD, Robertson C, Sheikh A, McMenamin J. Lancet Infect Dis. 2012 Jun 25. [Epub ahead of print]
PMID: 22738894 [PubMed - as supplied by publisher]
[Related citations](#)

☒ 3. [Knowledge, Attitudes, and Behaviors of Low-Income Women Considered High Priority for Receiving the Novel Influenza A \(H1N1\) Vaccine](#)

Boyd CA, Gazmararian JA, Thompson WW. Matern Child Health J. 2012 Jun 24. [Epub ahead of print]
PMID: 22729697 [PubMed - as supplied by publisher]
[Related citations](#)

Choose Destination

☐ File ☐ Clipboard
☐ Collections ☐ E-mail
☐ Order ☐ My Bibliography

☒ Citation manager

Generate a file for use with external citation management software.

Download 5 citations.

Create File

2

3

4

PubMed Central

Immunogenicity and Tolerability after Two Doses of Non-Adjuvant IPI LoS One. 2012

Choose Destination

Export to:

☒ EndNote
EndNote web

5

OK

Cancel

EndNote X6b4 - [My EndNote Library.enl]

File Edit References Groups Tools Window Help

J Amer College Cardiology Copy

Quick Search Show Search Panel

My Library

- All References (8)
- Imported References (5)
- Unfiled (5)
- Trash (0)
- My Groups
 - influenza (3)
- Online Search
 - Cambridge Books Online (0)
 - Hong Kong Inst of Educ (0)
 - Library of Congress (0)
 - LISTA (EBSCO) (0)
 - PubMed (NLM) (0)
 - Washington State Lib (0)
 - Web of Science (TS) (0)
 - Web of Science AHCI ... (0)
 - more...
- Find Full Text

Author	Year	Title
Aljadhhey, H.; Aly...	2012	The Safety of H1N1 Vaccine in Children in Saud...
Andrisani, G.; Fr...	2012	Immune response to influenza A/H1N1 vaccin...
Boyd, C. A.; Gaz...	2012	Knowledge, Attitudes, and Behaviors of Low-I...
Candela, S.; Perg...	2012	An early (3-6 weeks) active surveillance stud...
Simpson, C. R.; R...	2012	Effectiveness of H1N1 vaccine for the preventi...

Reference Preview Attached PDFs

Reference Type: Journal Article

Rating

Author
Boyd, C. A.
Gazmararian, J. A.
Thompson, W. W.

Year
2012

Title
Knowledge, Attitudes, and Behaviors of Low-Income Women Considered High Priority for Receiving the Novel Influenza A (H1N1) Vaccine

Journal
Matern Child Health J

Volume

Issue

Pages

Start Page

Epub Date
2012/06/26

Date
Jun 24

Type of Article

Short Title

Alternate Journal
Maternal and child health journal

ISSN
1573-6628 (Electronic)
1002-7875 (Online)

Showing 5 of 5 references in Group. (All References: 8)

Layout

可利用layout調整版面的呈現

The screenshot shows the EndNote X6b4 interface. The top menu bar includes File, Edit, References, Groups, Tools, Window, and Help. The toolbar contains various icons for file operations and searching. The main window is divided into three panes: a left sidebar, a central list of references, and a right pane for the selected reference.

Left Sidebar:

- My Library:** All References (13), Imported References (5), Unfiled (0), Trash (0).
- My Groups:** H1N1 vaccine (10), influenza (3).
- Online Search:** Cambridge Books Online (0), Hong Kong Inst of Educ (0), Library of Congress (0), LISTA (EBSCO) (0), PubMed (NLM) (0), Washington State Lib (0), Web of Science (TS) (0), Web of Science AHCI ... (0), more...
- Find Full Text:** Found PDF (1), Found URL (7), Not found (2).

Central List:

Author	Year	Title
Dao, T. T.; Nguye...	2012	Curcuminoids from Curcuma longa and their i...
Guan, J.; Chan, ...	2012	Comparing Escherichia coli O157:H7 Phage an...
Huy, C.; Kuhn, D.;	2012	Seasonal waves of influenza and cause-specifi...

Right Pane: Shows the selected reference details for Dao, T. T., Nguyen, P. H., Won, H. K., Kim, E. H., Park, J., Won, B. Y., & Oh, W. K. (2012). Curcuminoids from Curcuma longa and their inhibitory activities on influenza A neuraminidases. *Food Chemistry*, 134(1), 21-28. doi: 10.1016/j.foodchem.2012.02.015.

Layout Settings Panel (Bottom Right):

- Groups Panel:** Left (checked), Off.
- Reference Panel:** Right (checked), Right - Split, Bottom, Bottom - Split, Off.
- Layout:** (dropdown menu)

Annotations:

- A red box highlights the reference list and the right pane.
- A red box highlights the "Right" option in the Reference Panel.
- A red box highlights the "Layout" dropdown menu.
- A red box with the text "呈現在右邊" (Present on the right) is placed over the right pane.
- A blue circle with the number "5" is located near the bottom right corner.

Showing 3 of 3 references in Group. (All References: 13)

EndNote X6b4 - [My EndNote Library.enl]

File Edit References Groups Tools Window Help

APA 6th

Quick Search Show Search Panel

My Library	Author	Year	Title	Rating	Journal	Ref Type
All References (13)	Aljadhey, H.; Aly...	2012	The Safety of H1N1 Vaccine in Children in Saud...		Drug Saf	Journal Article
Imported References (5)	Andrisani, G.; Fr...	2012	Immune response to influenza A/H1N1 vaccin...		J Crohns Colitis	Journal Article
Unfiled (0)	Boyd, C. A.; Gaz...	2012	Knowledge, Attitudes, and Behaviors of Low-I...		Matern Child H...	Journal Article
Trash (0)	Candela, S.; Perg...	2012	An early (3-6 weeks) active surveillance stud...		Vaccine	Journal Article
My Groups	Lagler, H.; Grab...	2012	Immunogenicity and Tolerability after Two Do...		PLoS One	Journal Article
H1N1 vaccine (10)	Prematunge, C.; ...	2012	Factors influencing pandemic influenza vaccin...		Vaccine	Journal Article
influenza (3)	Purohit, S.; Alvar...	2012	Durable immune response to inactivated H1N...		Pediatr Blood C...	Journal Article
Online Search	Rebmann, T.; Iq...	2012	H1N1 Influenza Vaccine Compliance among Ho...		Infect Control ...	Journal Article
Cambridge Books Online (0)	Simpson, C. R.; R...	2012	Effectiveness of H1N1 vaccine for the preventi...		Lancet Infect ...	Journal Article
Hong Kong Inst of Educ (0)	Zhang, J.; While, ...	2012	Nurses' vaccination against pandemic H1N1 in...		Vaccine	Journal Article
Library of Congress (0)						
LISTA (EBSCO) (0)						
PubMed (NLM) (0)						
Washington State Lib (0)						
Web of Science (TS) (0)						
Web of Science AHCI ... (0)						
more...						
Find Full Text						
Found PDF (1)						
Found URL (7)						
Not found (2)						

Showing 10 of 10 references in Group. (All References: 13)

Reference Preview

Lagler, H., Grabmeier-Pfistershammer, K., Touzeau-Romer, V., Tobudic, S., Ramharter, M., Wenisch, J., ... Burgmann, H. (2012). Immunogenicity and Tolerability after Two Doses of Non-Adjuvanted, Whole-Virion Pandemic Influenza A (H1N1) Vaccine in HIV-Infected Individuals. *PLoS One*, 7(5), e36773. doi: 10.1371/journal.pone.0036773

呈現在下方

Lagler-2012-Immunogenicity and T.pdf

1 / 8 59%

OPEN ACCESS Freely available online

PLUS one

Immunogenicity and Tolerability after Two Doses of Non-Adjuvanted, Whole-Virion Pandemic Influenza A (H1N1) Vaccine in HIV-Infected Individuals

Heimo Lagler¹, Katharina Grabmeier-Pfistershammer², Veronika Touzeau-Römer³, Selma Tobudic², Michael Ramharter^{1,2}, Judith Wenisch⁴, Guido André Gualdoni¹, Monika Redlberger-Fritz¹, Theresia Popow-Kraupp⁵, Armin Rieger⁶, Heinz Burgmann^{1*}

¹ Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria, ² Department of Dermatology, Division of Immunology, Allergy and Infectious Diseases, Medical University of Vienna, Vienna, Austria, ³ Department of Tropical Medicine, University of Tübingen, Tübingen, Germany, ⁴ Department of Virology, Medical University of Vienna, Vienna, Austria

Abstract

Background: During the influenza pandemic of 2009/10, the whole-virion, virus-cell-derived, influenza A (H1N1) vaccine Celvapan® (Baxter) was used in Austria. Celvapan® is an adjuvant-free vaccine at that time in Europe. The objective of this observational, non-interventional, prospective study was to evaluate the immunogenicity and tolerability of two intramuscular doses of this novel vaccine in HIV-infected individuals.

Methods and Findings: A standard hemagglutination-inhibition (HAI) assay was used for evaluating the immunogenicity against the pandemic H1N1 strain. In addition, H1N1-specific IgG-antibodies were measured by a recently developed ELISA and compared with the HAI results. Tolerability of vaccination was evaluated after the second dose. A total of 79 HIV-infected adults with an indication for H1N1 vaccination were included in the study. 50 of the 79 participants had an HAI titre >1:40 and two patients showed a positive IgG-ELISA. The corresponding seroconversion rates were 31% after the first vaccination, increasing to 47% after the second, the corresponding seropositivity rates were 83% respectively. ELISA IgG levels were positive in 25% after the first vaccination and in 37% after the second. Younger age was clearly associated with higher seroconversion rates, whereas none of the seven patients >60 years of age <1:40 or seroconverted after vaccination. The vaccine was well tolerated.

Conclusion: The non-adjuvanted pandemic influenza A (H1N1) vaccine was well tolerated and induced a strong immune response in a sample of HIV-infected individuals.

Citation: Lagler H, Grabmeier-Pfistershammer K, Touzeau-Römer V, Tobudic S, Ramharter M, et al. (2012) Immunogenicity and Tolerability after Two Doses of Non-Adjuvanted, Whole-Virion Pandemic Influenza A (H1N1) Vaccine in HIV-Infected Individuals. *PLoS ONE* 7(5): e36773. doi:10.1371/journal.pone.0036773

Editor: John E. Tice, Saint Louis University, United States of America

Received: November 20, 2011 **Accepted:** April 9, 2012 **Published:** May 21, 2012

Copyright: © 2012 Lagler et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors have no support or funding to report.

Competing Interests: The authors have declared that no competing interests exist.

Groups Panel

Left

Off

Reference Panel

Right

Right - Split

Bottom

Bottom - Split

Off

Layout

標記書目為已讀或未讀狀態，
及以☆標示書目的重要程度。

The screenshot shows a library management software interface. The left sidebar contains navigation options like 'My Library', 'All References (292)', 'Sync Status...', 'Unfiled (265)', 'Trash (177)', 'My Groups' (with subgroups like '123 (0)', '2008 (13)', '2011 (36)', 'Chines (0)', 'new (6)', '腎臟 (19)', '農業 (8)', '蘇先生 (0)'), 'Online Search' (with options like 'Acad Search Pre...', 'Library of Congress', 'LISTA (EBSCO)', 'National Central L...', 'Natl Lib of Medicine', 'PubMed (NLM)', 'Web of Science (...)', 'more...'), and 'Find Full Text'.

The main table displays a list of references with the following columns: Author, Year, Title, Rating, Journal, and Ref Type. A red box highlights the Rating column, which contains star ratings from 1 to 5 stars. Another red box highlights the first column, which contains radio buttons for marking items as read or unread.

	Author	Year	Title	Rating	Journal	Ref Type
☐	梶田悦子; Ma...	2006	Nursing Health Guidelines for Osteoporosis B...	★★★★★	內蒙古醫學...	Journal Article
☐	Taramarcay, P...	2003	Intranasal corticosteroids for asthma control...	★★★★★	Cochrane Dat...	Electronic Art
☐	Theadom, Alice...	2009	Written emotional disclosure for asthma	★★★★	Cochrane Dat...	Electronic Art
☐	Abelsohn, A.; S...	2011	Health effects of outdoor air pollution: Appro...	★★★	Can Fam Phys...	Journal Article
☐	Walters Julia, A...	2009	Systemic corticosteroids for acute exacerbati...	★★	Cochrane Dat...	Electronic Art
☐	Walters Julia, A...	2010	Action plans with limited patient education o...	★	Cochrane Dat...	Government D
☒	Zhou, Yan; W...	2010	Monosodium glutamate avoidance for c...		Cochrane Da...	Electronic A
☒	Zhang, Y.; La...	2012	Acupuncture Use among American Adul...		Evid Based C...	Journal Arti
☒	Zhang, Y.; La...	2012	Acupuncture Use among American Adul...		Evid Based C...	Journal Arti
☐	Young, R. P.; H...	2011	How the genetics of lung cancer may overla...		Respirology	Journal Article
☒	Yorke, Janelle...	2005	Family therapy for asthma in children		Cochrane Da...	Electronic A
☒	Yorke, Janelle...	2006	Psychological interventions for adults ...		Cochrane Da...	Electronic A
☒	Yorke, Janelle...	2005	Psychological interventions for children...		Cochrane Da...	Electronic A
☒	Yoo, T. K.; Ch...	2012	Benign prostatic hyperplasia: from ben...		Korean J Urol	Journal Arti
☒	Yizhar, Ofer; ...	2011	Neocortical excitation/inhibition balanc...		Nature	Journal Arti
☒	Yang Ian, A.; ...	2007	Inhaled corticosteroids for stable chro...		Cochrane Da...	Electronic A
☒	Wood-Baker, ...	2000	Combined corticosteroid and long-actin...		Cochrane Da...	Electronic A
☒	Wolf, Zane Ro...	2012	Nursing Practice Breakdowns: Good an...		Medsurg Nur...	Journal Arti
☒	Wolf, Zane Ro...	2012	Nursing Practice Breakdowns: Good an...		Medsurg Nur...	Journal Arti
☒	Wolf, Fredric; ...	2002	Educational interventions for asthma in...		Cochrane Da...	Electronic A
☒	Whitehead, M...		Running Economy and Maximal Oxygen ...			Book
☒	Westby Marg...	2004	Anticholinergic agents for chronic asth...		Cochrane Da...	Electronic A
☒	Welsh Emma, ...	2010	Home-based educational interventions ...		Cochrane Da...	Electronic A
☒	Welsh Emma, ...	2010	Formoterol versus short-acting beta-a...		Cochrane Da...	Electronic A
☒	Welsh Emma, ...	2010	Caffeine for asthma		Cochrane Da...	Electronic A
☒	Wells, Margar...		Resilience, Physical Performance Meas...			Book

The screenshot displays the EndNote software interface. On the left is a sidebar with a tree view containing 'My Library' (with sub-items: All References (170), Search Results (3), Unfiled (152), Trash (3)), 'My Groups' (with sub-items: 2011 (5), child psychology (4), nature (13)), 'Online Search' (with sub-items: Library of Congress (0), LISTA (EBSCO) (0), PubMed (NLM) (0), Web of Science (TS) (0), and more...), and 'Find Full Text'. The main window features a search bar with 'Search' and 'Options' buttons, a 'Search Whole Library' dropdown, and checkboxes for 'Match Case' and 'Match Words'. Below the search bar is a search criteria table with a red box highlighting the first row: 'Rating' (dropdown), 'Is' (dropdown), and '★★★★★' (text input). The table has two more rows: 'And' 'Year' 'Contains' and 'And' 'Title' 'Contains'. The search results are shown in a table with columns: Author, Year, Title, Rating, Journal, and Ref Type. The results list three entries related to psychology and decision-making. At the bottom, there is a 'Reference' and 'Preview' pane. The 'Reference' pane shows 'Reference Type: Journal Article' and 'No References Selected'. The 'Preview' pane shows 'Attached PDFs' and a message: 'There are no PDFs attached to this reference.'

Author	Year	Title	Rating	Journal	Ref Type
Orne, M. T.	1962	ON THE SOCIAL-PSYCHOLOGY OF THE PSYCHOLOGI...	★★★★★	American Psycho...	Journal Artic...
Kahneman, D.; T...	1973	PSYCHOLOGY OF PREDICTION	★★★★★	Psychological ...	Journal Ar...
Tversky, A.; Kah...	1981	THE FRAMING OF DECISIONS AND THE PSYCHOL...	★★★★★	Science	Journal Ar...

全螢幕開啟PDF

Abstract

Background: During the influenza pandemic of 2009/10, the whole-virion, Vero-cell-derived, inactivated, pandemic influenza A (H1N1) vaccine Celvapan® (Baxter) was used in Austria. Celvapan® is adjuvant-free and was the only such vaccine at that time in Europe. The objective of this observational, non-interventional, prospective single-center study was to evaluate the immunogenicity and tolerability of two intramuscular doses of this novel vaccine in HIV-positive individuals.

Methods and Findings: A standard hemagglutination inhibition (HAI) assay was used for evaluation of the seroconversion rate and seroprotection against the pandemic H1N1 strain. In addition, H1N1-specific IgG antibodies were measured using a recently developed ELISA and compared with the HAI results. Tolerability of vaccination was evaluated up to one month after the second dose. A total of 79 HIV-infected adults with an indication for H1N1 vaccination were evaluated. At baseline, 55 of the 79 participants had an HAI titer $\geq 1:40$ and two patients showed a positive IgG ELISA. The seroconversion rate was 31% after the first vaccination, increasing to 41% after the second; the corresponding seroprotection rates were 92% and 83% respectively. ELISA IgG levels were positive in 25% after the first vaccination and in 37% after the second. Among the participants with baseline HAI titers $<1:40$, 63% seroconverted. Young age was clearly associated with lower HAI titers at baseline and with higher seroconversion rates, whereas none of the seven patients >60 years of age had a baseline HAI titer $<1:40$ or seroconverted after vaccination. The vaccine was well tolerated.

Conclusion: The non-adjuvanted pandemic influenza A (H1N1) vaccine was well tolerated and induced a measurable immune response in a sample of HIV-infected individuals.

Citation: Lagler H, Grabmeier-Pfisterhammer K, Touzeau-Römer V, Tobudic S, Ramharner M, et al. (2012) Immunogenicity and Tolerability after Two Doses of Non-Adjuvanted, Whole-Virion Pandemic Influenza A (H1N1) Vaccine in HIV-Infected Individuals. PLoS ONE 7(5): e36773. doi:10.1371/journal.pone.0036773

Editor: John E. Tavis, Saint Louis University, United States of America

Received: November 27, 2011; **Accepted:** April 5, 2012; **Published:** May 21, 2012

Copyright: © 2012 Lagler et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors have no support or funding to report.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: heinz.burgmann@meduniwien.ac.at

Introduction

A new swine-origin, triple-reassortant influenza A (H1N1) virus that emerged in Mexico in late March 2009 began to spread rapidly through human-to-human transmission outside the usual influenza season [1–3]. On June 11th, 2009, the World Health Organization raised the influenza pandemic alert to the highest level (level 6) as human influenza A (H1N1) cases were reported worldwide in 74 countries [4]. The pandemic virus was antigenically and genetically unrelated to human seasonal influenza virus, and former seasonal influenza vaccines appeared not protective. Reports of severe respiratory failure associated with this strain, particularly in young persons, forced the rapid

Medicines Agency (EMA) licensed an inactivated whole-virion, Vero-cell-derived pandemic H1N1 influenza A/Caifornia/07/2009 vaccine without adjuvant. This vaccine was based on an earlier H5N1 mock-up vaccine [3]. In Austria, the Federal Ministry of Health selected this vaccine for use during the national pandemic vaccination campaign from November 2009 to March 2010 and therefore it was the only available pandemic vaccine in Austria during the whole of the pandemic period. At this time international guidelines from the Centers for Disease Control and Prevention recommended vaccination [5] particularly for immunocompromised individuals, since underlying medical conditions such as immunosuppression appeared to predispose for infection with H1N1 [2]. Immunosuppressed patients are at increased risk

Reference Preview Lagler-2012-Imm

1 / 8

Open PDF
 Open this PDF in a reference window.

Non-Adjuvanted, Whole-Virion Pandemic Influenza A (H1N1) Vaccine in HIV-Infected Individuals

Helmut Lagler^{1*}, Katharina Grabmeier-Pfisterhammer², Veronique Touzeau-Römer³, Selma Tobudic⁴, Michael Ramharner^{5,6}, Judith Muenich⁷, Gudrun Andrich-Gastner⁸, Barbara Radlinger-Peter⁹, Theresia Poppe-Braunp¹⁰, Armin Rieger¹¹, Heinz Burgmann¹²

¹Department of Medical Clinical Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria, ²Department of Dermatology Division of Dermatology, Allergy and Infectious Diseases, Medical University of Vienna, Vienna, Austria, ³Department of Tropical Medicine, University of Hamburg, Hamburg, Germany, ⁴Department of Virology, Medical University of Vienna, Vienna, Austria

Abstract

Background: During the influenza pandemic of 2009/10, the whole-virion, Vero-cell-derived, inactivated, pandemic influenza A (H1N1) vaccine Celvapan® (Baxter) was used in Austria. Celvapan® is adjuvant-free and was the only such vaccine at that time in Europe. The objective of this observational, non-interventional, prospective single-center study was to evaluate the immunogenicity and tolerability of two intramuscular doses of this novel vaccine in HIV-positive individuals.

Methods and Findings: A standard hemagglutination inhibition (HAI) assay was used for evaluation of the seroconversion rate and seroprotection against the pandemic H1N1 strain. In addition, H1N1-specific IgG antibodies were measured using a recently developed ELISA and compared with the HAI results. Tolerability of vaccination was evaluated up to one month after the second dose. A total of 79 HIV-infected adults with an indication for H1N1 vaccination were evaluated. At baseline, 55 of the 79 participants had an HAI titer $\geq 1:40$ and two patients showed a positive IgG ELISA. The seroconversion rate was 31% after the first vaccination, increasing to 41% after the second; the corresponding seroprotection rates were 92% and 83% respectively. ELISA IgG levels were positive in 25% after the first vaccination and in 37% after the second. Among the participants with baseline HAI titers $<1:40$, 63% seroconverted. Young age was clearly associated with lower HAI titers at baseline and with higher seroconversion rates, whereas none of the seven patients >60 years of age had a baseline HAI titer $<1:40$ or seroconverted after vaccination. The vaccine was well tolerated.

Conclusion: The non-adjuvanted pandemic influenza A (H1N1) vaccine was well tolerated and induced a measurable immune response in a sample of HIV-infected individuals.

Citation: Lagler H, Grabmeier-Pfisterhammer K, Touzeau-Römer V, Tobudic S, Ramharner M, et al. (2012) Immunogenicity and Tolerability after Two Doses of Non-Adjuvanted, Whole-Virion Pandemic Influenza A (H1N1) Vaccine in HIV-Infected Individuals. PLoS ONE 7(5): e36773. doi:10.1371/journal.pone.0036773

Editor: John E. Tavis, Saint Louis University, United States of America

Received: November 27, 2011; **Accepted:** April 5, 2012; **Published:** May 21, 2012

Copyright: © 2012 Lagler et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors have no support or funding to report.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: heinz.burgmann@meduniwien.ac.at

Introduction

A new swine-origin, triple-reassortant influenza A (H1N1) virus that emerged in Mexico in late March 2009 began to spread rapidly through human-to-human transmission outside the usual influenza season [1–3]. On June 11th, 2009, the World Health Organization raised the influenza pandemic alert to the highest level (level 6) as human influenza A (H1N1) cases were reported worldwide in 74 countries [4]. The pandemic virus was antigenically and genetically unrelated to human seasonal influenza virus, and former seasonal influenza vaccines appeared not protective. Reports of severe respiratory failure associated with this strain, particularly in young persons, forced the rapid development of a vaccine and resulted in development of several pandemic anti-influenza A (H1N1) 2009 vaccines to be distributed around the world [1–3]. In October 2009, in addition to vaccine adjuvanted pandemic H1N1 vaccines, the European

Medicines Agency (EMA) licensed an inactivated whole-virion, Vero-cell-derived pandemic H1N1 influenza A/Caifornia/07/2009 vaccine without adjuvant. This vaccine was based on an earlier H5N1 mock-up vaccine [3]. In Austria, the Federal Ministry of Health selected this vaccine for use during the national

07/10/2012 01:43 ...
 Note:記得要引用

PLoS ONE | www.plosone.org

可直接E-mail書目和PDF檔給他人(限Outlook)

Endl
File

File



 **E-mail PDF**
Attach a copy of this PDF to an e-mail.

OPEN ACCESS Freely available online

 PLoS one

Immunogenicity and Tolerability after Two Doses of Non-Adjuvanted, Whole-Virion Pandemic Influenza A (H1N1) Vaccine in HIV-Infected Individuals

Heimo Lagler¹, Katharina Grabmeier-Pfistershammer², Veronique Touzeau-Römer², Selma Tobudic¹, Michael Ramharter^{1,3}, Judith Wenisch¹, Guido Andrés Gualdoni¹, Monika Redlberger-Fritz⁴, Theresia Popow-Kraupp⁴, Armin Rieger², Heinz Burgmann^{1*}

1 Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria, **2** Department of Dermatology, Division of Immunology, Allergy and Infectious Diseases, Medical University of Vienna, Vienna, Austria, **3** Department of Tropical Medicine, University of Tübingen, Tübingen, Germany, **4** Department of Virology, Medical University of Vienna, Vienna, Austria

Abstract

Background: During the influenza pandemic of 2009/10, the whole-virion, Vero-cell-derived, inactivated, pandemic influenza A (H1N1) vaccine Celvapan® (Baxter) was used in Austria. Celvapan® is adjuvant-free and was the only such vaccine at that time in Europe. The objective of this observational, non-interventional, prospective single-center study was to evaluate the immunogenicity and tolerability of two intramuscular doses of this novel vaccine in HIV-positive individuals.

Methods and Findings: A standard hemagglutination inhibition (HAI) assay was used for evaluation of the seroconversion rate and seroprotection against the pandemic H1N1 strain. In addition, H1N1-specific IgG antibodies were measured using a recently developed ELISA and compared with the HAI results. Tolerability of vaccination was evaluated up to one month after the second dose. A total of 79 HIV-infected adults with an indication for H1N1 vaccination were evaluated. At baseline, 55 of the 79 participants had an HAI titer $\geq 1:40$ and two patients showed a positive IgG ELISA. The seroconversion rate was 31% after the first vaccination, increasing to 41% after the second; the corresponding seroprotection rates were 92% and 83% respectively. ELISA IgG levels were positive in 25% after the first vaccination and in 37% after the second. Among the participants with baseline HAI titers $< 1:40$, 63% seroconverted. Young age was clearly associated with lower HAI titers at

Sentence case.

lowercase

UPPERCASE

Capitalize Each Word

TOGGLE cASE

在每一筆書目編輯畫面中，
可自行修改字體的大小寫
呈現方式。

EndNote X6 - [Sample_Library_X6.enl]

File Edit References Groups **Tools** Window Help

Numbered

My Library ▾

- All References
- Unfiled
- Trash

Psychology 101

- Biopsychology
- Clinical Psychology
- Cognitive Psychology
- Converted Search
- Counseling Psychology

Social Sciences

- Linguistics

Biology

- Anatomy

Bats

- Chiroptera

Search Library... Ctrl+F

Spell Check Ctrl+Y

Cite While You Write [CWYW]

Online Search...

Format Paper

Change/Move/Copy Fields...

Sync

Open Term Lists

Define Term Lists... Ctrl+4

Link Term Lists... Ctrl+3

Sort Library...

Recover Library...

Library Summary...

Subject Bibliography...

Manuscript Templates...

Quick Search

Year	Title
2012	Bioactive derivatives of curcumin atten...
2004	Ecological, taxonomic, and physiological...
2012	OPA3 -Related Autosomal Dominant Op...

Change/Move/Copy Fields功能，可針對書目欄位做新增或修改。

Change/Move/Copy Fields

Change Fields | Move/Copy Fields

In: **Select a field...** **Insert Special**

Change

- ☒ Insert after field's text:
- ☐ Insert before field's text:
- ☐ Replace whole field with:
- ☐ Clear field
- ☐ Change case

Sentence case.





☒ Include a space before the new text

☒ Include a space after the new text

B I U P A¹ A₁ Σ


確定 取消 說明

Sync.同步備份(NEW!)



EN Web上的
資料夾備份
到單機上

單機上已設
的資料夾



Sync同步的偏好設定

The screenshot shows the EndNote X6 application window with the 'EndNote Preferences' dialog box open. The 'Sync' tab is selected in the left sidebar. The 'Enable Sync' button is highlighted. The 'EndNote Web Account Credentials' section shows the 'E-mail Address' field filled with 'ellie@srts.com.tw' and the 'Password' field filled with '*****'. The 'Sync this EndNote Library' section shows the library path 'C:\Documents and Settings\All Users\Docum...Sample_Library_X6.enl'. The 'Sync Automatically' section has three checkboxes: 'When I open the library' (unchecked), 'When I close the library' (unchecked), and 'Every 15 minutes' (checked). The 'Every 15 minutes' dropdown menu is open, showing options: 'Every 15 minutes', 'Every 30 minutes', and 'Every 60 minutes'. The 'Every 60 minutes' option is highlighted. The 'Sync' button in the left sidebar is also highlighted.

1. Edit menu

2. Preferences...

3. Sync

點選此鈕可
註冊新帳號

Enable Sync

EndNote Web Account Credentials

E-mail Address: ellie@srts.com.tw

Password: *****

Sync this EndNote Library

C:\Documents and Settings\All Users\Docum...Sample_Library_X6.enl

Sync Automatically:

☐ When I open the library

☐ When I close the library

☒ Every 15 minutes

Every 15 minutes

Every 30 minutes

Every 60 minutes

確定 取消 套用(A)

輸入帳號
讓系統保
持記憶

可更改同
步頻率

Sync. 同步備份的注意事項

- A **two-year** subscription to EndNote Web comes with the purchase of EndNote X6. The free subscription allows you to create an EndNote Web library of up to 100,000 references and up to **5 GB** (gigabytes) of data in file attachments.
- Sync includes groups and group associations but does **not include group sets, smart groups, and groups within combination groups**. These will be added in a later release.
- Sync will put groups where a group set cannot be identified in an **Unfiled Groups** set. Drag and drop the group to the appropriate group in the desktop library.
- All file attachments that you transferred in an earlier version of EndNote are replaced with the **actual file attachments**.
- Sync works with only **one library and one EndNote Web account**.
- **You can always cancel a Sync process** that is currently in progress. However, EndNote processes all information that has gone through the Sync process up to the cancellation point.
- If you have a **ResearcherID account**, then your My Publications list and **Publication Lists 1 and 2 will be displayed in Unfiled Groups**. You can create a ResearcherID group set in the desktop library and drag and drop those groups into it.

Thank You!

碩睿資訊有限公司

服務電話

02-77315800

服務信箱

services@customer-support.com.tw

服務網址

<http://www.sris.com.tw>